The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?
{{output}}
The Losartan Intervention for Endpoint Reduction trial is one of several end-point trials that are now available with angiotensin-receptor blockers. This trial compared two regimens-losartan-based therapy to atenolol-based therapy-in 9193 hypertensive patients... ...
